The Challenge
A critical Phase III cardiovascular trial restart was placed at immediate risk when a previous supplier failed to deliver six essential standard-of-care (AxMP) medications across 17 clinical sites in Turkey.
With no room for delay, the consequences were significant: missed dosing windows, inactive sites, and further disruption to study timelines and costs. The sponsor required a partner capable of acting decisively within a complex local market.
The BAP Pharma Approach
BAP Pharma mobilised immediately, combining local market expertise with rapid decision-making to design a sourcing and on-demand distribution model in under one week.
Working through a trusted Turkish partner, the team secured all six required medications while streamlining requirements, including the removal of non-essential labelling steps to accelerate deployment.
Within 48–72 hours, all 17 sites were qualified and ready to receive product. A responsive supply model enabled temperature-controlled deliveries within 24–48 hours of request, supported by full documentation and end-to-end traceability.
The Outcome
BAP Pharma’s solution enabled the sponsor to quickly re-initiate enrolment and progress new site initiations without further supply disruption. Patient treatment remained on track, study momentum was restored, and the sponsor regained control of a highly time-critical trial phase.
By moving decisively and reducing supply risk at speed, BAP Pharma helped protect both patient access and the wider commercial investment behind the study.
